Nessan is an Operating Partner at Khosla Ventures focused on life science companies with an emphasis on nucleic acid editing, novel delivery systems, gene and cell therapy, novel target identification and data analytics for drug discovery and development.
Having founded multiple companies in the life sciences realm, Nessan is a serial biotech entrepreneur and investor. Most notable among his companies are Intellia Therapeutics, a top-10 biotech startup in 2014, Triplet Therapeutics, and Korro Bio. At Intellia, Nessan served as president and CEO from inception through 2017, leading the company from concept through partner deals, multiple financing rounds and an IPO prior to its second anniversary.
Nessan also held investment roles at Atlas Venture and Omega Fund Management, where he successfully invested in and managed multiple investments across the United States and Europe. He is currently the executive chair at Everyone Medicines and Korro Bio. He also currently sits on the board of Amide, Bionaut Labs, Deep Genomics, Kamau Therapeutics, Liberate Bio, Ochre Bio and Stylus Biomedicine and is a board observer with Eligo Bioscience.
Previously he was a member of the equity research team at UBS, an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London, and was a Howard Hughes Associate Fellow at Baylor College of Medicine.
